The incidence and predictors of overall adverse effects caused by low dose amiodarone in real-world clinical practice |
Kim, Hack-Lyoung
(Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine)
Seo, Jae-Bin (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) Chung, Woo-Young (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) Kim, Sang-Hyun (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) Kim, Myung-A (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) Zo, Joo-Hee (Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine) |
1 | Haffajee CI, Love JC, Alpert JS, Asdourian GK, Sloan KC. Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. Am Heart J 1983;106(4 Pt 2):935-943. DOI ScienceOn |
2 | Tavares AB, Paula SK, Vaisman M, Teixeira Pde F. Amiodarone and thyrotoxicosis: case reports. Arq Bras Cardiol 2010; 95:e122-e124. DOI |
3 | Nademanee K, Singh BN, Hendrickson J, et al. Amiodarone in refractory life-threatening ventricular arrhythmias. Ann Intern Med 1983;98(5 Pt 1):577-584. DOI |
4 | Parra O, Ruiz J, Ojanguren I, Navas JJ, Morera J. Amiodarone toxicity: recurrence of interstitial pneumonitis after withdrawal of the drug. Eur Respir J 1989;2:905-907. |
5 | Kang HM, Kang YS, Kim SH, et al. Amiodarone-induced hepatitis and polyneuropathy. Korean J Intern Med 2007;22:225-229. DOI ScienceOn |
6 | Kwon KH, Jeong SW, Uh S, et al. A case of amiodarone-associated pulmonary toxicity. Korean J Intern Med 1995;10:155-159. DOI |
7 | Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-798. DOI ScienceOn |
8 | Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920. DOI ScienceOn |
9 | Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009;30:1245-1253. DOI ScienceOn |
10 | Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-674. DOI ScienceOn |
11 | Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237. DOI ScienceOn |
12 | Jackevicius CA, Tom A, Essebag V, et al. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol 2011;108:705-710. DOI ScienceOn |
13 | AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003;42:20-29. DOI ScienceOn |
14 | Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-1424. DOI ScienceOn |
15 | Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294-1303. DOI ScienceOn |
16 | Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone: Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160:1741-1748. DOI ScienceOn |
17 | Santangeli P, Di Biase L, Burkhardt JD, et al. Examining the safety of amiodarone. Expert Opin Drug Saf 2012;11:191-214. DOI ScienceOn |
18 | Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005;118:706-714. DOI ScienceOn |
19 | Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22:240-254. |
20 | Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol 2008;6:228-236. DOI ScienceOn |
21 | Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med 1995;122:689-700. DOI ScienceOn |
22 | Ernawati DK, Stafford L, Hughes JD. Amiodarone-induced pulmonary toxicity. Br J Clin Pharmacol 2008;66:82-87. DOI ScienceOn |
23 | Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989;9:679-685. DOI |
24 | Mantyjarvi M, Tuppurainen K, Ikaheimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998;42:360-366. DOI ScienceOn |
25 | Camus P, Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Clin Chest Med 2004;25:65-75. DOI ScienceOn |
26 | Oyama N, Oyama N, Yokoshiki H, et al. Detection of amiodarone-induced pulmonary toxicity in supine and prone positions: high-resolution computed tomography study. Circ J 2005;69:466-470. DOI ScienceOn |
27 | Weinberg BA, Miles WM, Klein LS, et al. Five-year follow- up of 589 patients treated with amiodarone. Am Heart J 1993;125:109-120. DOI ScienceOn |
28 | Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007;71:1610-1616. DOI ScienceOn |
![]() |